)
)
Thor Medical Investor Relations Material
Latest events
Q4 2024
Thor Medical
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Thor Medical
Access all reports
Segment Data
Access more data
Non-current assets by
Geography
Norway
Expenses by
Financials
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutic products for hematological cancers in Norway. The company is developing Betalutin, an antibody radionuclide conjugate, which is in Phase III clinical trial for a range of non-Hodgkin lymphoma indications. It is also developing 177Lu-lilotomab satetraxetan (HH1), a targeted alpha immunotherapy for non-Hodgkin lymphomas. The company has strategic collaboration with NRCF to develop treatment regimens for hematological cancers and other indications using Lutathera or Betalutin; and with Servier S.A.S., as well as Cytodyn Inc.
Key slides for Thor Medical
Q4 2024
Thor Medical
Q4 2024
Thor Medical
Latest articles
)
Adobe: Equipping the Architects of Digital Expression
The story of how Adobe grew from a small garage upstart to one of the largest and most dominant software companies in the world.
21 Mar 2025
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
Ticker symbol
TRMED
Country
🇳🇴 Norway